Related references
Note: Only part of the references are listed.Cautious Hope for Cannabidiol (CBD) in Rheumatology Care
Mary-Ann Fitzcharles et al.
ARTHRITIS CARE & RESEARCH (2023)
An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom
Jonathan Paul Liebling et al.
CANNABIS AND CANNABINOID RESEARCH (2022)
Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms
Ewa Galaj et al.
NEUROPHARMACOLOGY (2020)
Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis
Tory R. Spindle et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2020)
Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study
Alex Capano et al.
POSTGRADUATE MEDICINE (2020)
The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial
Salahaden R. Sultan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities
Dixon H. Xu et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2020)
Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
E. Appiah-Kusi et al.
PSYCHOPHARMACOLOGY (2020)
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Sinemyiz Atalay et al.
ANTIOXIDANTS (2020)
Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease
Han Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Edward Chesney et al.
NEUROPSYCHOPHARMACOLOGY (2020)
The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights
Willian Lazarini-Lopes et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2020)
Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol
Kevin Madden et al.
PEDIATRICS (2020)
Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users
Tory R. Spindle et al.
DRUG AND ALCOHOL DEPENDENCE (2020)
Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans: A Pharmacokinetic Study in Healthy Subjects
Jose Alexandre S. Crippa et al.
CANNABIS AND CANNABINOID RESEARCH (2020)
Labeling of Cannabidiol Products: A Public Health Perspective
Jamie Corroon et al.
CANNABIS AND CANNABINOID RESEARCH (2020)
The proposed mechanisms of action of CBD in epilepsy
Royston A. Gray et al.
EPILEPTIC DISORDERS (2020)
Immune Responses Regulated by Cannabidiol
James M. Nichols et al.
CANNABIS AND CANNABINOID RESEARCH (2020)
Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors
Mylyne Tham et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice
Fabio Arturo Iannotti et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial
Daniel G. Couch et al.
INFLAMMATORY BOWEL DISEASES (2019)
A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
Lesley Taylor et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial
Yasmin L. Hurd et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy
James W. Wheless et al.
CNS DRUGS (2019)
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
Thomas R. Arkell et al.
PSYCHOPHARMACOLOGY (2019)
Cannabidiol Affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 Receptors and Has Peripheral Sympathomimetic Effects in Spontaneously Hypertensive and Normotensive Rats
Rafal Kossakowski et al.
FRONTIERS IN PHARMACOLOGY (2019)
Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy
Angela K. Birnbaum et al.
EPILEPSIA (2019)
Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study
Hery Chung et al.
PLOS ONE (2019)
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
Joshua D. Brown et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Cannabidiol Interacts Significantly with Everolimus-Report of a Patient with Tuberous Sclerosis Complex
Adelheid Wiemer-Kruel et al.
NEUROPEDIATRICS (2019)
Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors
Alice Hartmann et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2019)
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects
Nadia Solowij et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2019)
The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids
Justin L. Poklis et al.
FORENSIC SCIENCE INTERNATIONAL (2019)
An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia
Tine van de Donk et al.
PAIN (2019)
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Ila M. Linares et al.
BRAZILIAN JOURNAL OF PSYCHIATRY (2019)
Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review
Jasmine Turna et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2019)
The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group
Harneet Hundal et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal
Chandni Hindocha et al.
ADDICTION (2018)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Localization of cannabinoid receptors CB1, CB2, GPR55, and PPAR alpha in the canine gastrointestinal tract
Giorgia Galiazzo et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2018)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis
Peter M. Irving et al.
INFLAMMATORY BOWEL DISEASES (2018)
Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis
Stefania Petrosino et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs et al.
PSYCHOPHARMACOLOGY (2018)
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study
Jerzy P. Szaflarski et al.
EPILEPSY & BEHAVIOR (2018)
Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
Celia J. A. Morgan et al.
TRANSLATIONAL PSYCHIATRY (2018)
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Lesley Taylor et al.
CNS DRUGS (2018)
Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial
Kerri A. Schoedel et al.
EPILEPSY & BEHAVIOR (2018)
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Sophie A. Millar et al.
FRONTIERS IN PHARMACOLOGY (2018)
Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases
Jacqueline S. Gofshteyn et al.
JOURNAL OF CHILD NEUROLOGY (2017)
Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels
Luciano R. Vilela et al.
EPILEPSY & BEHAVIOR (2017)
Labeling Accuracy of Cannabidiol Extracts Sold Online
Marcel O. Bonn-Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Whole-body biodistribution of the cannabinoid type 1 receptor ligand [18F]MK-9470 in the rat
H. G. Buchholz et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
Cannabidiol: State of the art and new challenges for therapeutic applications
Simona Pisanti et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life
Antonio W. Zuardi et al.
Frontiers in Pharmacology (2017)
Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders
Jonathan L. C. Lee et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study
Khalid A. Jadoon et al.
JCI INSIGHT (2017)
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial
Timna Naftali et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers
Shanna Babalonis et al.
DRUG AND ALCOHOL DEPENDENCE (2017)
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis
Margaret Haney et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors
A. G. Sartim et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice
Andreza B. Sonego et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
Khalid A. Jadoon et al.
DIABETES CARE (2016)
Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex
Evan J. Hess et al.
EPILEPSIA (2016)
Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study
Moshe Yeshurun et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
Sumner Burstein
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
John M. McPartland et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R. B. Laprairie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Alexandra L. Geffrey et al.
EPILEPSIA (2015)
Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner
Massimo Nabissi et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Cannabidiol as a Potential Treatment for Anxiety Disorders
Esther M. Blessing et al.
NEUROTHERAPEUTICS (2015)
Molecular Targets of Cannabidiol in Neurological Disorders
Clementino Ibeas Bih et al.
NEUROTHERAPEUTICS (2015)
Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
Fabio Arturo Iannotti et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review
Stephen M. Stout et al.
DRUG METABOLISM REVIEWS (2014)
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
Orrin Devinsky et al.
EPILEPSIA (2014)
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-
Maria Beatrice Morelli et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial
Marcos Hortes N. Chagas et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings
Celia J. A. Morgan et al.
ADDICTIVE BEHAVIORS (2013)
Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
Massimo Nabissi et al.
CARCINOGENESIS (2013)
Cannabidiol administration into the bed nucleus of the stria terminalis alters cardiovascular responses induced by acute restraint stress through 5-HT1A receptor
Felipe V. Gomes et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Amir Englund et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers
R. Martin-Santos et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors
Felipe V. Gomes et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Alline Cristina Campos et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
Alexandre Rafael de Mello Schier et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
Luciano De Petrocellis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
Jose Alexandre S. Crippa et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
Mateus M. Bergamaschi et al.
NEUROPSYCHOPHARMACOLOGY (2011)
The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
Felipe V. Gomes et al.
PSYCHOPHARMACOLOGY (2011)
Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors
Vanessa de Paula Soares et al.
BEHAVIOURAL BRAIN RESEARCH (2010)
Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors
T. V. Zanelati et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
The Nonpsychoactive Cannabinoid Cannabidiol Inhibits 5-Hydroxytryptamine3A Receptor-Mediated Currents in Xenopus laevis Oocytes
Keun-Hang Yang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
Sagnik Bhattacharyya et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors
Fernando H. F. Alves et al.
PHARMACOLOGICAL RESEARCH (2010)
Distinct Effects of Delta 9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing
Paolo Fusar-Poli et al.
ARCHIVES OF GENERAL PSYCHIATRY (2009)
5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats
Leonardo B. M. Resstel et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Cannabidiol for the treatment of psychosis in Parkinson's disease
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition
Stefan J. Borgwardt et al.
BIOLOGICAL PSYCHIATRY (2008)
5-lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid
P. Massi et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study
Ileana Tomida et al.
JOURNAL OF GLAUCOMA (2006)
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma
Alessia Ligresti et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Identification and functional characterization of brainstem cannabinoid CB2 receptors
MD Van Sickle et al.
SCIENCE (2005)
Agonistic properties of cannabidiol at 5-HT1a receptors
EB Russo et al.
NEUROCHEMICAL RESEARCH (2005)
Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain:: An immunohistochemical study
E Núñez et al.
SYNAPSE (2004)
Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies
W Notcutt et al.
ANAESTHESIA (2004)
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms
DT Wade et al.
CLINICAL REHABILITATION (2003)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
T Bisogno et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Share Paper
